Latest news with #Imfinzi
Yahoo
a day ago
- Business
- Yahoo
AstraZeneca announces $50 billion U.S. manufacturing investment, matching its big pharma peers
AstraZeneca (AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers that have, combined, announced more than $200 billion in investments in coming years. The commitment is the largest investment to-date, according to the company in a statement Monday. It includes expansions of current sites, including in Maryland and Massachusetts, as well as new facility in Virginia. "The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of the-art centre will produce small molecules, peptides and oligonucleotides," the company said. U.K.-based AstraZeneca said it currently relies on the U.S. market for 42% of its revenues, and hopes to increase the U.S. market share to 50% with this move. Its known for oncology drugs Tagrisso and Imfinzi. AstraZeneca's leadership was scheduled to speak at an event in Washington, D.C. Monday evening, flanked by Virginia Gov. Glenn Youngkin and U.S. Commerce Dept. representatives. "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030," said CEO Pascal Soriot. The strategy to invest billions in manufacturing is one being deployed by the industry in order to curry favor with President Donald Trump and his re-shoring agenda, and in hopes of avoiding strict tariffs on imported drug components manufactured abroad. Some of the largest investment commitments to-date have been Johnson & Johnson's (JNJ) $55 billion announcement and Eli Lilly's (LLY) $50 billion. With a previous $3.5 billion announced in November 2024, the new $50 billion commitment puts AstraZeneca in second. Trump has promised the pharma industry will face tariffs starting August 1. Industry leaders have pleaded with the administration for more time, and Trump has hinted the tariffs could be phased-in, as the companies work to bring their manufacturing onshore. The industry has been hoping Trump would ease up on the tariffs, in exchange for the onshoring commitments. J&J CFO Joe Wolk recently told Yahoo Finance the company has met with Trump and tried to persuade him to understand that the industry can't move facilities overnight. Meanwhile, others, like Eli Lilly CEO Dave Ricks, are hoping the administration would halt tariffs on the industry altogether. Ricks previously said that if the administration wants a commitment to make generics and other low-revenue products in exchange for no tariffs, its something the industry could consider. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-07-2025
- Business
- Yahoo
AstraZeneca PLC (AZN) Secures EU Approval for Imfinzi
AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs' top healthcare stock picks. On July 4, the company secured regulatory approval for Imfinzi (durvalumab). The approval is for the use of the drug for the treatment of muscle-invasive bladder cancer (MIBC). The regulatory approval by the European Commission follows a positive opinion by the Committee for Medicinal Products for Human Use. It also comes on the heels of the company delivering positive results from the NIAGARA Phase III trial. 'The NIAGARA results showed how this regimen reduced the risk of recurrence by nearly a third and significantly extended survival, underscoring its potential to transform clinical practice in this curative-intent setting,' Dr. Michiel Van der Heijden, medical oncologist and Group Leader at the Netherlands Cancer Institute, and investigator in the NIAGARA trial, said. With the regulatory approval, AstraZeneca stands to target over 30,000 people in the five major European countries struggling with respectable muscle-invasive bladder cancer (MIBC). AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. It operates in key therapeutic areas, including oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory, immunology, and rare diseases. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Green Energy Penny Stocks to Buy Right Now and 10 Most Popular AI Penny Stocks to Buy According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
15-07-2025
- Business
- Business Upturn
Astrazeneca Pharma shares jump 3% after company gets CDSCO approval for import, sale of bladder cancer drug
By Aman Shukla Published on July 15, 2025, 09:47 IST AstraZeneca Pharma shares surged 3% today after the company received a key regulatory nod from India's Central Drugs Standard Control Organisation (CDSCO). The approval allows AstraZeneca to import and sell its cancer drug Durvalumab (branded as Imfinzi) in India for an additional use. This new approval covers two dosage forms—120 mg/2.4 ml and 500 mg/10 ml—and expands Imfinzi's indication to treat adult patients with muscle invasive bladder cancer (MIBC). Specifically, the drug can now be used in combination with gemcitabine and cisplatin as a neoadjuvant (pre-surgery) treatment. After surgery (radical cystectomy), Imfinzi can continue as a standalone adjuvant (post-surgery) therapy. The expanded label marks a significant milestone for AstraZeneca in India's oncology market, particularly in bladder cancer treatment. The company can now begin marketing Imfinzi for this new use, subject to any further clearances that may be needed. Imfinzi is already approved globally for other cancer indications, including lung and biliary tract cancers. This latest CDSCO approval adds another layer to its growing clinical footprint in India. AstraZeneca Pharma shares opened at ₹9,195.00 and touched a high of ₹9,650.50 during the day. The stock did not fall below its opening price, marking ₹9,195.00 as the low. Over the past year, the stock has seen a 52-week high of ₹10,691.00 and a low of ₹6,220.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
News18
15-07-2025
- Business
- News18
Stocks To Watch: HDFC Life, HDB Financial, HCL Tech, RVNL, Sun Pharma, And Others
Last Updated: Stocks to watch: Shares of firms like HDFC Life, HDB Financial, HCL Tech, RVNL, Sun Pharma, and others will be in focus on Tuesday's trade Stocks to Watch on July 15, 2025: Markets opened the week on a volatile note, extending recent losses to close nearly half a percent lower. On Tuesday, attention will remain on a slew of companies announcing their first-quarter earnings, including HDFC Life, HDB Financial, HCL Tech, Tata Technologies, and Rallis India, among others. Q1 Results Today Key earnings are expected from HDFC Life, ICICI Lombard, ICICI Prudential, HDB Financial Services, Bank of Maharashtra, and Just Dial. HCL Technologies HCLTech revised its EBIT margin guidance for FY26 to 17–18%, down from 18–19%, following margin pressure in Q1. EBIT margins declined 160 basis points QoQ to 16.3% for the June quarter. Tata Technologies The company posted a 10% YoY drop in net profit at Rs 170 crore, with USD revenue down 2.1% QoQ and constant currency revenue falling 4.6%. Rail Vikas Nigam Ltd received a Letter of Award from DMRC to construct a 7.298 km viaduct and seven metro station platforms under Delhi Metro Phase-IV. RailTel bagged a Rs 264 crore order from East Central Railway to implement the Kavach collision avoidance system across 607 km. AstraZeneca Pharma Received approval from CDSCO to import and market Durvalumab (Imfinzi) in India for an additional indication in cancer treatment. Sun Pharma Launched LEQSELVI 8 mg tablets in the US for severe alopecia areata, following a litigation settlement with Incyte Corporation. Power Mech Projects Won two O&M contracts worth Rs 551.35 crore, including a major project for SJVN's Buxar plant in Bihar. Oberoi Realty The CoC of Hotel Horizon approved a Rs 919 crore resolution plan submitted by a consortium including Oberoi Realty. Inox Wind The board will meet on July 17 to consider fundraising through equity or other instruments. LIC R Doraiswamy has officially taken charge as CEO & MD of LIC for a three-year term, ending August 2028. Tejas Networks Posted a net loss of Rs 193.9 crore for Q1 FY26, compared to a Rs 77.5 crore profit a year earlier. Revenue dropped 87% YoY, largely due to BSNL-related delays. Deepak Fertilisers Signed a Rs 1,200 crore regasification contract with Petronet LNG. Meson Valves India Received an order worth Rs 46.26 lakh from Mazagon Dock to supply submarine fuel system components. Disclaimer:Disclaimer: The views and investment tips by experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions. view comments First Published: July 15, 2025, 08:02 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Yahoo
14-07-2025
- Business
- Yahoo
AstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension Trial
AstraZeneca recently experienced a weekly price move of 2% amid announcements that could have supported its momentum. The successful Phase III trial results for Baxdrostat, targeting a significant global need for hypertension treatments, likely provided a positive catalyst. Additionally, the European Union's approval of Imfinzi for a new cancer indication may have added further support. These developments occurred against a backdrop of flat overall market performance, with major indexes barely changing as global investors assessed trade policy uncertainties and awaited key financial data releases. We've identified 3 warning signs with AstraZeneca and understanding the impact should be part of your investment process. Find companies with promising cash flow potential yet trading below their fair value. The recent developments for AstraZeneca, particularly the successful Phase III trial results for Baxdrostat and the EU's approval of Imfinzi, could significantly enhance the company's revenue and earnings forecasts. These breakthroughs address substantial medical needs in hypertension and cancer, potentially expanding AstraZeneca's market share and boosting prescription sales. Combined with AstraZeneca's global strategic initiatives, these news items reinforce the company's narrative of growth through innovation and market expansion. Over the past five years, AstraZeneca has achieved a total shareholder return of 25.87%. This long-term performance provides a broader context compared to the recent weekly share price movement of 2%. While AstraZeneca underperformed both the UK market with a return of 5.9% and the UK Pharmaceuticals industry with a negative return of 9.3% over the past year, the strong long-term total returns highlight the company's resilience and potential for enduring growth. As analysts have set a price target of £135.83, approximately 30% above the current share price of £107.28, these recent developments may positively influence future investor sentiment. The new advancements in AstraZeneca's product pipeline and expansion in emerging markets bolster the expectation of future revenue, aligning with analysts' forecasts of significant earnings improvements over the next few years. The current share price discount to the analyst price target could suggest that the market has not yet fully realized the potential upside of these recent achievements. Gain insights into AstraZeneca's future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:AZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
